How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Biopharmaceutical Cold Chain Logistics Market
- By Temperature Range: Frozen Cold Chain (-25°C to -15°C), Refrigerated Cold Chain (2°C to 8°C), Controlled Room Temperature (15°C to 25°C)
- By Service Type: Transportation Services, Warehousing and Storage, Packaging Solutions, Cold Chain Monitoring and Tracking, Customs Clearance and Documentation
- By Mode of Transportation: Air Freight, Road Freight, Sea Freight, Rail Freight
- By End-User: Pharmaceutical Manufacturers, Biotechnology Companies, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Healthcare Providers
- By Packaging Type: Passive Packaging, Active Packaging, Reusable Packaging, Single-use Packaging
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Frozen Cold Chain (-25°C to -15°C) leads By Temperature Range at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Biopharmaceutical Cold Chain Logistics Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Temperature Range 3
Service Type 5
Mode of Transportation 4
End-User 5
Packaging Type 4
Companies profiled
DHL Supply Chain
Kuehne + Nagel
FedEx Custom Critical
UPS Healthcare
World Courier (a part of AmerisourceBergen)
Marken (a UPS company)
Cryoport
Bomi Group
Envirotainer
Panalpina (now part of DSV)
DB Schenker
Agility Logistics
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →DHL Supply Chain
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Kuehne + Nagel
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →FedEx Custom Critical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →UPS Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →World Courier (a part of AmerisourceBergen)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Marken (a UPS company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cryoport
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bomi Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Envirotainer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Panalpina (now part of DSV)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →DB Schenker
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Agility Logistics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Ceva Logistics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Seko Logistics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Santos Express
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,954M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Frozen Cold Chain (-25°C to -15°C)48.7
- Refrigerated Cold Chain (2°C to 8°C)30.2
- Controlled Room Temperature (15°C to 25°C)21.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,103M → $1,536M · 4.2%
Europe$768.8M → $1,205M · 5.8%
Asia Pacific$702.0M → $1,008M · 4.6%
Latin America$434.5M → $607.2M · 4.3%
Middle East and Africa$334.3M → $454.7M · 3.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.992026
5.002027
5.022028
5.022029
5.042030
5.062031
5.072032
5.072033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- DHL Supply Chain12.2
- Kuehne + Nagel19.5
- FedEx Custom Critical10.6
- UPS Healthcare5.8
- World Courier (a part of AmerisourceBergen)13.6
- Marken (a UPS company)10.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Temperature Range27.4%
Service Type18.4%
Mode of Transportation29.5%
End-User13.4%
Packaging Type11.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe25.0
- Asia Pacific21.0
- Latin America12.6
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| DHL Supply Chain | 94 | 97 | 84 | 89 | 78 | 84 | 88 |
| Kuehne + Nagel | 71 | 75 | 70 | 84 | 72 | 86 | 76 |
| FedEx Custom Critical | 64 | 79 | 83 | 72 | 67 | 70 | 73 |
| UPS Healthcare | 72 | 79 | 64 | 73 | 59 | 82 | 72 |
| World Courier (a part of AmerisourceBergen) | 58 | 52 | 56 | 75 | 55 | 65 | 60 |
| Marken (a UPS company) | 61 | 71 | 55 | 62 | 71 | 50 | 62 |
| Cryoport | 42 | 46 | 53 | 59 | 65 | 54 | 53 |
| Bomi Group | 60 | 47 | 58 | 43 | 47 | 60 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- DHL Supply Chain
- Kuehne + Nagel
- FedEx Custom Critical
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| DHL Supply Chain | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Kuehne + Nagel | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| FedEx Custom Critical | − | ✓ | ◐ | ◐ | ✓ | ◐ |
| UPS Healthcare | ✓ | ◐ | − | − | − | ✓ |
| World Courier (a part of AmerisourceBergen) | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Marken (a UPS company) | ◐ | ◐ | ◐ | ✓ | ◐ | − |
| Cryoport | − | ◐ | − | ◐ | ◐ | ◐ |
| Bomi Group | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1DHL Supply Chain88
2Kuehne + Nagel76
3FedEx Custom Critical73
4UPS Healthcare72
5Marken (a UPS company)62
6World Courier (a part of AmerisourceBergen)60
7Cryoport53
8Bomi Group53
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
DHL Supply Chain
Challenger3
Strong scale, closing on the leaders.
Kuehne + NagelFedEx Custom CriticalUPS Healthcare
Contender2
Focused players with pockets of strength.
World Courier (a part of AmerisourceBergen)Marken (a UPS company)
Niche2
Specialists in a single segment or region.
CryoportBomi Group
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Temperature Range in North America, then scale across Biopharmaceutical Cold Chain Logistics Market — a $245M beachhead inside a $3.70B market.
Beachhead (SOM)$245Mobtainable near-term
Serviceable (SAM)$1.40Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Frozen Cold Chain (-25°C to -15°C)
Best fit — highest urgency & budget in Temperature Range.
Economic buyer79 fit
Refrigerated Cold Chain (2°C to 8°C)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Controlled Room Temperature (15°C to 25°C)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Temperature Range in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mode of Transportation
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Temperature Range leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biopharmaceutical Cold Chain Logistics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation15%
Closed-won8%
$18.6KCAC
$90KLTV
4.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Biopharmaceutical Cold Chain Logistics Market is a resilient opportunity — $4.21B by 2033, compounding at 3.2%.
TAM · 2025$3.27Btoday
TAM · 2033$4.21Bforecast
CAGR3.2%2027–2033
Cumulative$33.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.21BTotal addressable market
SAM$1.55BServiceable available market
SOM$268MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.2% CAGR
Demand compounds through 2033, outpacing GDP across Temperature Range.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Temperature Range moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.21BLarge & growingTAM by 2033 at 3.2% CAGR
$1.55BServiceable nowreachable with today’s model
$268MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.28BBear2.1% CAGR
$4.21BBase3.2% CAGR
$5.39BBull4.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Biopharmaceutical Cold Chain Logistics Market — a $6.73B market by 2033. Plan: grow share from 6.9% to 15.1%.
Market size · 2033$6.73Btotal addressable
Market CAGR10.5%2027–2033
Target share15.1%from 6.9% today
Revenue ambition$1.02Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 15.1% | At risk |
| Revenue | $471M | $1.02B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.9% | 43.4% | Ahead |
| Customer retention | 84.2% | 94.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Temperature Range
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Service Type capability
A defensible second engine — invest in Service Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Temperature Range share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Service Type
- Authorise North America expansion plan
- Fund R&D program for Temperature Range leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Biopharmaceutical Cold Chain Logistics Market conversation — a $2.22B market you can size, segment and defend in minutes.
Market size · 2033$2.22Btotal opportunity
Growth5.5%CAGR to 2033
Addressable buyers1,341+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Temperature Range
Goal Grow share in Temperature Range
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 3 mopayback period
$95K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
DHL Supply ChainKuehne + NagelFedEx Custom CriticalUPS HealthcareWorld Courier (a part of AmerisourceBergen)Marken (a UPS company)CryoportBomi Group+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biopharmaceutical Cold Chain Logistics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biopharmaceutical Cold Chain Logistics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Protein Drugs Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View report3-lead ECG Cables and Lead Wires Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportOphthalmology Instrumentation Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View report3-Iodo-1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View report3-Iodo-1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine (Cas# 151266-23-8) Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View report3-in-1 Oral CBCT Market
Market size, share, segmentation and regional forecast.
$925M market · 2025 base year
View reportMobile Medical Imaging Services Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportHospital Capacity Management Solutions Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View report3-Fluoro-4-methoxyphenylacetic Acid Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View report3D X-ray Microscope Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View report3D X-ray Imaging Systems Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View report3D X-Ray Computed Tomography Machine (3D X-Ray CT) Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.